Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses

Endocrinology

Volumn 142, Issue 1, 2001, Pages 464-476

  Southgate, Tom D ^a   Stone, Daniel ^a   Williams, Judith C ^a   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOHYPOPHYSIS HORMONE; CD8 ANTIGEN; CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; NEUTRALIZING ANTIBODY; PROLACTIN; THYMIDINE KINASE; THYROTROPIN;

ADENOHYPOPHYSIS; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE;

EID: 0035117983     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.1.7898     Document Type: Article

References (33)

1. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long term expression, cell cycle dependency, and effects on hormone secretion
2. High efficiency method for gene transfer in normal pituitary gonadotropes: Adenoviral-mediated expression of G protein-coupled receptor kinase 2 suppresses luteinizing hormone secretion
3. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas
4. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride induced hyperplasic anterior pituitaries
5. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy
6. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors
7. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clincial trials
8. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: Reduced cytotoxicity of a truncated HSV1-TK
9. Constitutive and enhanced expression from the CMV major IE-promoter in a defective adenovirus vector
10. Cell type specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is expressed from herpes virus or adenovirus vectors
11. The use of adenovirus vectors to transfer genes to identified brain cells in vitro
12. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks
13. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus
14. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
15. Clinical evaluation of a two-site immunoradiometric assay for adrenocorticotrophin in unextracted human plasma using monoclonal antibodies
16. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases
17. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
18. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
19. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle
20. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain
21. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo
22. Humoral immune responses to adenovirus vectors in the brain
23. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
24. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
25. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants
26. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NF-κB
27. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production
28. Repression of retrovirus-mediated transgene expression by interferons: Implications for gene therapy
29. Interferon-alpha inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF-κB activity
30. Differential dependence of ACTH secretion induced by various cytokines on the integrity of the paraventricular nucleus
31. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
32. Persistence in muscle of an adenoviral vector that lacks all viral genes